See more : Canadian National Railway Company (CNI) Income Statement Analysis – Financial Results
Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hard to Treat Diseases Inc. (HTDS) Income Statement Analysis – Financial Results
- Collins Foods Limited (CLLFF) Income Statement Analysis – Financial Results
- L’Oréal S.A. (OR.SW) Income Statement Analysis – Financial Results
- Continental Holdings Corporation (3703.TW) Income Statement Analysis – Financial Results
- Inforich Inc. (9338.T) Income Statement Analysis – Financial Results
Intra-Cellular Therapies, Inc. (ITCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | 0.00 | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
| Cost of Revenue | 33.75M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
| Gross Profit Ratio | 92.73% | 91.79% | 90.17% | 91.59% | -687.16% | 0.00% | -32,205.56% | -28,273.44% | -52.82% | -3,576.82% | -741.34% | -396.68% |
| Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| General & Administrative | 317.66M | 272.98M | 190.11M | 150.06M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Selling & Marketing | 92.20M | 85.80M | 82.50M | 36.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Other Expenses | 0.00 | -1.18M | -2.10M | -282.23K | 0.00 | 0.00 | -245.84K | -330.70K | -60.71K | -29.76K | 0.00 | 0.00 |
| Operating Expenses | 590.01M | 492.32M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
| Interest Expense | 0.00 | 7.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.78K | 0.00 | 7.07K | 612.96K | 193.50K |
| Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |
| EBITDA | -158.85M | -262.97M | -285.16M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| EBITDA Ratio | -34.21% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -40,203.17% | -34,872.43% | -115,815.85% | -5,314.87% | -957.76% | -523.31% |
| Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
| Operating Income Ratio | -34.32% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -41,832.65% | -35,759.96% | -115,815.85% | -5,367.52% | -959.69% | -526.09% |
| Total Other Income/Expenses | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.90M | 1.02M | 296.86K | -583.35K | -154.50K |
| Income Before Tax | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Income Before Tax Ratio | -29.94% | -102.86% | -347.73% | -1,007.48% | -243,711.05% | 0.00% | -40,203.17% | -34,883.55% | -114,696.75% | -5,316.09% | -981.01% | -531.04% |
| Income Tax Expense | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
| Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Net Income Ratio | -30.08% | -102.86% | -347.73% | -1,007.54% | -243,713.69% | 0.00% | -39,771.64% | -35,205.79% | -114,698.50% | -5,316.37% | -981.67% | -532.10% |
| EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| Weighted Avg Shares Out | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Weighted Avg Shares Out (Dil) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy?
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet
Source: https://incomestatements.info
Category: Stock Reports